留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

常染色体显性遗传性多囊肾病肾移植临床技术操作规范(2022版)

中华医学会器官移植学分会. 常染色体显性遗传性多囊肾病肾移植临床技术操作规范(2022版)[J]. 器官移植, 2023, 14(1): 24-30. doi: 10.3969/j.issn.1674-7445.2023.01.003
引用本文: 中华医学会器官移植学分会. 常染色体显性遗传性多囊肾病肾移植临床技术操作规范(2022版)[J]. 器官移植, 2023, 14(1): 24-30. doi: 10.3969/j.issn.1674-7445.2023.01.003
Branch of Organ Transplantation of Chinese Medical Association. Clinical technical operation specification of kidney transplantation for autosomal dominant polycystic kidney disease (2022 edition)[J]. ORGAN TRANSPLANTATION, 2023, 14(1): 24-30. doi: 10.3969/j.issn.1674-7445.2023.01.003
Citation: Branch of Organ Transplantation of Chinese Medical Association. Clinical technical operation specification of kidney transplantation for autosomal dominant polycystic kidney disease (2022 edition)[J]. ORGAN TRANSPLANTATION, 2023, 14(1): 24-30. doi: 10.3969/j.issn.1674-7445.2023.01.003

常染色体显性遗传性多囊肾病肾移植临床技术操作规范(2022版)

doi: 10.3969/j.issn.1674-7445.2023.01.003
基金项目: 

国家自然科学基金 82070765

医学免疫学国家重点实验室开放课题 NKMI2020K05

蛋白质组学国家重点实验室开放课题 SKLPO202009

详细信息
  • 中图分类号: R617, R692

Clinical technical operation specification of kidney transplantation for autosomal dominant polycystic kidney disease (2022 edition)

  • 摘要: 常染色体显性遗传性多囊肾病(ADPKD)是最常见的遗传性肾病,也是终末期肾病(ESRD)的最常见原因之一。肾移植是ADPKD伴ESRD患者的最佳肾脏替代治疗方式,目前国内外学者对于ADPKD患者肾移植前多囊肾是否需要切除存在一定的争议,并且多囊肾切除手术标准及手术方式也不尽相同。为进一步规范ADPKD患者肾移植的临床技术操作,中华医学会器官移植学分会组织器官移植学专家从ADPKD的诊断、ADPKD肾移植的适应证和禁忌证、术前评估及处理、多囊肾切除术、术后管理等方面,制定本规范。

     

  • 图  1  多囊肾外科手术介入时机及手术方式推荐

    Figure  1.  The recommended timing of intervention and operation method in polycystic kidney surgery

  • [1] ANSELMO A, IARIA G, PELLICCIARO M, et al. Native nephrectomy in patients with autosomal dominant polycystic kidney disease evaluated for kidney transplantation[J]. Transplant Proc, 2019, 51(9): 2914-2916. DOI: 10.1016/j.transproceed.2019.08.010.
    [2] CORNEC-LE GALL E, ALAM A, PERRONE RD. Autosomal dominant polycystic kidney disease[J]. Lancet, 2019, 393(10174): 919-935. DOI: 10.1016/S0140-6736(18)32782-X.
    [3] BEVILACQUA M, GRADIN S, WILLIAMS J, et al. The BC ADPKD network: a comprehensive provincial approach to support specialized and locally delivered multidisciplinary ADPKD care[J]. Can J Kidney Health Dis, 2021, 8: 20543581211035218. DOI: 10.1177/20543581211035218.
    [4] PEI Y, OBAJI J, DUPUIS A, et al. Unified criteria for ultrasonographic diagnosis of ADPKD[J]. J Am Soc Nephrol, 2009, 20(1): 205-212. DOI: 10.1681/ASN.2008050507.
    [5] IRAZABAL MV, RANGEL LJ, BERGSTRALH EJ, et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials[J]. J Am Soc Nephrol, 2015, 26(1): 160-172. DOI: 10.1681/ASN.2013101138.
    [6] AKBARI P, NASRI F, DENG SX, et al. Total kidney volume measurements in ADPKD by 3D and ellipsoid ultrasound in comparison with magnetic resonance imaging[J]. Clin J Am Soc Nephrol, 2022, 17(6): 827-834. DOI: 10.2215/CJN.14931121.
    [7] RAJ S, SINGH RG, DAS P. Mutational screening of PKD1 and PKD2 in Indian ADPKD patients identified 95 genetic variants[J]. Mutat Res, 2020, 821: 111718. DOI: 10.1016/j.mrfmmm.2020.111718.
    [8] HATEBOER N, V DIJK MA, BOGDANOVA N, et al. Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group[J]. Lancet, 1999, 353(9147): 103-107. DOI: 10.1016/s0140-6736(98)03495-3.
    [9] MALLAWAARACHCHI AC, LUNDIE B, HORT Y, et al. Genomic diagnostics in polycystic kidney disease: an assessment of real-world use of whole-genome sequencing[J]. Eur J Hum Genet, 2021, 29(5): 760-770. DOI: 10.1038/s41431-020-00796-4.
    [10] NIELSEN ML, LILDBALLE DL, RASMUSSEN M, et al. Clinical genetic diagnostics in Danish autosomal dominant polycystic kidney disease patients reveal possible founder variants[J]. Eur J Med Genet, 2021, 64(4): 104183. DOI: 10.1016/j.ejmg.2021.104183.
    [11] CHAPMAN AB, DEVUYST O, ECKARDT KU, et al. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference[J]. Kidney Int, 2015, 88(1): 17-27. DOI: 10.1038/ki.2015.59.
    [12] LUBENNIKOV AE, PETROVSKⅡ NV, KRUPINOV GE, et al. Bilateral nephrectomy in patients with autosomal dominant polycystic kidney disease and end-stage chronic renal failure[J]. Nephron, 2021, 145(2): 164-170. DOI: 10.1159/000513168.
    [13] PIERRE M, MOREAU K, BRACONNIER A, et al. Unilateral nephrectomy versus renal arterial embolization and technique survival in peritoneal dialysis patients with autosomal dominant polycystic kidney disease[J]. Nephrol Dial Transplant, 2020, 35(2): 320-327. DOI: 10.1093/ndt/gfz200.
    [14] ZHOU C, GU Y, MEI C, et al. Dialysis modality and mortality in polycystic kidney disease[J]. Hemodial Int, 2018, 22(4): 515-523. DOI: 10.1111/hdi.12673.
    [15] DARIUS T, BERTONI S, DE MEYER M, et al. Simultaneous nephrectomy during kidney transplantation for polycystic kidney disease does not detrimentally impact comorbidity and graft survival[J]. World J Transplant, 2022, 12(5): 100-111. DOI: 10.5500/wjt.v12.i5.100.
    [16] GADELKAREEM RA, ABDELGAWAD AM, MOHAMMED N. Simultaneous kidney transplantation and ipsilateral native nephrectomy in patients with autosomal dominant polycystic kidney disease[J]. World J Transplant, 2022, 12(9): 310-312. DOI: 10.5500/wjt.v12.i9.310.
    [17] XU J, D'SOUZA K, LAU NS, et al. Staged versus concurrent native nephrectomy and renal transplantation in patients with autosomal dominant polycystic kidney disease: a systematic review[J]. Transplant Rev (Orlando), 2022, 36(1): 100652. DOI: 10.1016/j.trre.2021.100652.
    [18] TSAI TY, CHEN CH, WU MJ, et al. Outcomes of kidney transplantation in patients with autosomal dominant polycystic kidney disease: our experience based on 35-years follow-up[J]. Diagnostics (Basel), 2022, 12(5): 1174. DOI: 10.3390/diagnostics12051174.
    [19] PRUDHOMME T, BOISSIER R, HEVIA V, et al. Native nephrectomy and arterial embolization of native kidney in autosomal dominant polycystic kidney disease patients: indications, timing and postoperative outcomes. a systematic review[J]. Minerva Urol Nephrol, 2022, DOI: 10.23736/S2724-6051.22.04972-2[Epub ahead of print].
    [20] HAN JH, JEONG SH, YUK HD, et al. Safety and feasibility of synchronous unilateral nephrectomy and contralateral heminephrectomy for extremely severe autosomal dominant polycystic kidney disease: techniques and outcome[J]. Investig Clin Urol, 2022, 63(3): 341-349. DOI: 10.4111/icu.20210461.
    [21] JEAN RA, ALEXANDRE M, YOO PS. Kidney transplantation with and without native nephrectomy for polycystic kidney disease: results of the national inpatient sample and the rationale for a 2-staged procedure[J]. J Am Coll Surg, 2018, 226(6): 1079-1084. DOI: 10.1016/j.jamcollsurg.2017.11.021.
    [22] PRABHU M, DAMLE NA, RAY A, et al. 18F-FDG PET/CT in cyst infection in autosomal dominant polycystic kidney disease[J]. Indian J Radiol Imaging, 2020, 30(1): 102-104. DOI: 10.4103/ijri.IJRI_469_18.
    [23] 常染色体显性多囊肾病临床实践指南专家委员会. 中国常染色体显性多囊肾病临床实践指南(第二版)[J]. 临床肾脏病杂志, 2019, 19(4): 227-235. DOI: 10.3969/j.issn.1671-2390.2019.04.001.

    Expert Committee on Clinical Practice Guidelines for Autosomal Dominant Polycystic Kidney Disease. Chinese clinical practice guide for autosomal dominant polycystic kidney disease[J]. J Clin Nephrol, 2019, 19(4): 227-235. DOI: 10.3969/j.issn.1671-2390.2019.04.001.
    [24] 张磊, 张健, 田野, 等. 后腹腔镜联合Gibson切口多囊肾切除一期同种异体肾移植术3例报道并文献复习[J]. 临床和实验医学杂志, 2017, 16(8): 747-749. DOI: 10.3969/j.issn.1671-4695.2017.08.007.

    ZHANG L, ZHANG J, TIAN Y, et al. Simultaneous retroperitoneoscopic nephrectomy and kidney transplantation using Gibson incision with autosomal dominant polycystic kidney disease: report of three cases and literature review[J]. J Clin Exp Med, 2017, 16(8): 747-749. DOI: 10.3969/j.issn.1671-4695.2017.08.007.
    [25] TSUKAMOTO S, URATE S, YAMADA T, et al. Comparative efficacy of pharmacological treatments for adults with autosomal dominant polycystic kidney disease: a systematic review and network meta-analysis of randomized controlled trials[J]. Front Pharmacol, 2022, 13: 885457. DOI: 10.3389/fphar.2022.885457.
    [26] QIAN Q, DU H, KING BF, et al. Sirolimus reduces polycystic liver volume in ADPKD patients[J]. J Am Soc Nephrol, 2008, 19(3): 631-638. DOI: 10.1681/ASN.2007050626.
    [27] WU LZ, WENG YQ, LING YX, et al. A Web of Science-based scientometric analysis about mammalian target of rapamycin signaling pathway in kidney disease from 1986 to 2020[J]. Transl Androl Urol, 2021, 10(3): 1006-1017. DOI: 10.21037/tau-20-1469.
    [28] 中华医学会器官移植学分会. 器官移植免疫抑制剂临床应用技术规范(2019版)[J]. 器官移植, 2019, 10(3): 213-226. DOI: 10.3969/j.issn.1674-7445.2019.03.001.

    Branch of Organ Transplantation of Chinese Medical Association. Technical specifcation for clinical application of immunosuppressive agents in organ transplantation (2019 edition)[J]. Organ Transplant, 2019, 10(3): 213-226. DOI: 10.3969/j.issn.1674-7445.2019.03.001.
    [29] JUNG Y, IRAZABAL MV, CHEBIB FT, et al. Volume regression of native polycystic kidneys after renal transplantation[J]. Nephrol Dial Transplant, 2016, 31(1): 73-79. DOI: 10.1093/ndt/gfv227.
    [30] YAMAMOTO T, WATARAI Y, KOBAYASHI T, et al. Kidney volume changes in patients with autosomal dominant polycystic kidney disease after renal transplantation[J]. Transplantation, 2012, 93(8): 794-798. DOI: 10.1097/TP.0b013e318246f910.
    [31] MAHAJAN S, NARAYANAN V, BHATIA V, et al. Anesthetic considerations for a patient with autosomal dominant polycystic kidney disease, having a ruptured intracranial aneurysm for endovascular coiling: a case report[J]. Asian J Neurosurg, 2022, 17(2): 379-382. DOI: 10.1055/s-0042-1750811.
    [32] ECONIMO L, ZENI L, CORTINOVIS R, et al. ADPKD and intracranial aneurysms: indications for screening, follow-up and clinical management[J]. G Ital Nefrol, 2021, 38(5): 2021-vol5.
  • 加载中
图(2)
计量
  • 文章访问数:  43
  • HTML全文浏览量:  4
  • PDF下载量:  9
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-10-21
  • 网络出版日期:  2023-01-17
  • 刊出日期:  2023-01-15

目录

    /

    返回文章
    返回